COMPANY
BiomeSense
NIH awards 3
- NIH award 5R44TR003744-03 FY2026: $676,980 awarded for that fiscal year; activity R44 (SBIR); PI NICHOLS, DYLAN; recipient as written: BIOMESENSE, INC., CHICAGO, IL. Development of a Novel Biosensor to Accelerate Inv source ↗
- NIH award 2R44TR003744-02A1 FY2025: $1,117,161 awarded for that fiscal year; activity R44 (SBIR); PI NICHOLS, DYLAN; recipient as written: BIOMESENSE, INC., CHICAGO, IL. Development of a Novel Biosensor to Accelerate source ↗
- NIH award 1R43TR003744-01 FY2021: $294,404 awarded for that fiscal year; activity R43 (SBIR); PI NICHOLS, DYLAN; recipient as written: BIOMESENSE, INC., CHICAGO, IL. Development of a Novel Biosensor to AccelerateInve source ↗
Funding and NIH signals
- SEC Form D raise Raised $7.06M (Form D filed Nov 3, 2025). SEC Form D 0001789915-25-000002 (Nov 3, 2025)
Evidence (1 event)
- Nov 3, 2025 · SEC Form D 0001789915-25-000002
Name of Issuer: BiomeSense, Inc.; CIK: 1789915; Address: Chicago, IL; Submission type: D; Filing date: 2025-11-03; Industry Group: Biotechnology; Date of First Sale: 2025-07-18; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 7250000; Total Amount Sold: 7059599; Federal exemptions: 06b
- Nov 3, 2025 · SEC Form D 0001789915-25-000002
- NIH award NIH awarded $677K (SBIR Phase II 5R44TR003744-03, continuation, notice Jun 16, 2026). NIH RePORTER 5R44TR003744-03 (Jun 16, 2026)
Evidence (1 event)
- Jun 16, 2026 · NIH RePORTER 5R44TR003744-03
Organization: BIOMESENSE, INC.; City/State: CHICAGO, IL; Project number: 5R44TR003744-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 676980; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome; Organization type: Domestic For-Profits
- Jun 16, 2026 · NIH RePORTER 5R44TR003744-03